Balancing Innovation and Access to Medicines
This page is under construction as of 3/4/09. Please send comments or additions to Mike Palmedo at mpalmedo@wcl.american.edu.PIJIP Documents
- Rebecca Wolf. Prize Fund Proposals Literature Reivew. (February 19, 2009).
- Sean Flynn. Balancing Access and Innovation in Poor Countries. (October 2, 2007).
- SeanFlynn. Economic Justifications for Open Access to Essential DrugPatents. Presentation of Working Paper. (September 28, 2007).
KEI Documents
- Selected Innovation Prizes and Reward Programs. March 7, 2008).
- James Love. The Role of Prizes in Developing Low-Cost, Point-of-Care Rapid Diagnostic Tests and Better Drugs for Tuberculosis. MSF expert meeting on IGWG and R&D for tuberculosis.
- James Love. Prizes, not prices, to stimulate antibiotic R&D. SciDev.Net. (March 26, 2009).
- James Love and Tim Hubbard. The Big Idea: Prizes to Stimulate R&D for New Medicines. Chicago-Kent Law Review, Volume 82, Number 3 (November, 2007).
- KEI Hompage
- PIJIP/KEI Event: Achieving Innovation + Access in Global Pharmaceutical Markets
- Stanford Documents
- National Legislative Association on Prescription Drug Prices (NLARx) Documents
- PIJIP Blogs
- S. 2210 - The Medical Innovation Prize Fund Act of 2007, (October 19, 2007)
- Expert Comments on the Medical Innovation Prize Fund Act, (October 19, 2007)
- PressRelease from John Edwards' Presidential Campaingn. Making Health CareAffordable, Accountable, and Universal. (June 14, 2007)
WHO Intergovernmental Working Group on Public Health, Innovation, and Intellectual Property
- Homepage for the Intergovernmental Working Group
- Submissions to the IGWG from Member States
- Knowledge Ecology International Page on the Intergovernmental Working Group
Other Documents
